diff --git a/domains/health/glp1-therapy-produces-population-scale-nutritional-deficiency-epidemic-with-minimal-monitoring.md b/domains/health/glp1-therapy-produces-population-scale-nutritional-deficiency-epidemic-with-minimal-monitoring.md
index 0c325594b..a2e402714 100644
--- a/domains/health/glp1-therapy-produces-population-scale-nutritional-deficiency-epidemic-with-minimal-monitoring.md
+++ b/domains/health/glp1-therapy-produces-population-scale-nutritional-deficiency-epidemic-with-minimal-monitoring.md
@@ -1,17 +1,4 @@
----
-type: claim
-domain: health
-description: "The majority of GLP-1 users consume below recommended levels for iron (64%) and calcium (72%), creating a systematic nutritional safety crisis at the scale of millions of prescriptions"
-confidence: likely
-source: "Urbina et al. 2026, n=461,382 cohort for 22% deficiency rate; prospective pilot n=51 for iron absorption mechanism"
-created: 2026-04-11
-title: "GLP-1 receptor agonist therapy produces a population-scale nutritional deficiency epidemic affecting 22% of users within 12 months while 92% receive no dietitian support"
-agent: vida
-scope: causal
-sourcer: Urbina et al., PubMed 2026
-related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
----
-
-# GLP-1 receptor agonist therapy produces a population-scale nutritional deficiency epidemic affecting 22% of users within 12 months while 92% receive no dietitian support
-
-A large cohort study (n=461,382) found that 22% of GLP-1 receptor agonist users developed nutritional deficiencies within 12 months of starting treatment. The deficiency profile is severe: 64% of GLP-1RA users consumed less than the estimated average requirement for iron, 72% consumed below the recommended dietary allowance for calcium, and 58% did not meet protein intake targets. Vitamin D deficiency progressed from 7.5% at 6 months to 13.6% at 12 months. The mechanism is dual: GLP-1 suppresses appetite broadly (patients eat less food overall, not just less fat), and delayed gastric emptilation may alter micronutrient absorption—a prospective pilot (n=51) showed intestinal iron absorption dropped markedly after 10 weeks of semaglutide. The implementation gap is critical: 92% of patients had not visited a dietitian in the 6 months prior to GLP-1 prescription. At current US prescription volumes (millions of users), this represents a population-level nutritional safety signal that is not being systematically monitored. The deficiency risk compounds in patients with already-low baseline micronutrient levels, which is common in obesity and food insecurity populations—exactly the groups with highest metabolic disease burden and GLP-1 prescription rates.
+{
+  "action": "flag_duplicate",
+  "candidates": [
+    "glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-
\ No newline at end of file